Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




AI Outperforms Expert Pathologists in Predicting Lung Cancer Spread

By LabMedica International staff writers
Posted on 12 Mar 2024

For years, the medical community has been struggling with the challenge of predicting which lung cancer patients are most likely to experience metastasis. This knowledge is crucial for treating early-stage non-small cell lung cancer (NSCLC) patients, as it influences whether they should undergo aggressive treatments like chemotherapy or radiation after lung surgery. Over half of stage I–III NSCLC patients eventually face brain metastasis, but for many others, such intensive treatments are unnecessary. Now, researchers have found that artificial intelligence (AI) could be a promising tool in aiding physicians with these critical decisions.

A groundbreaking pilot study conducted by Caltech (Pasadena, CA, USA) and Washington University School of Medicine in St. Louis (WUSTL, St. Louis, Mo, USA) revealed AI's capability to outperform expert pathologists in predicting the likelihood of cancer metastasis in NSCLC patients. The study involved training a deep-learning network, a sophisticated type of AI program, using hundreds of thousands of image tiles derived from biopsy images of 118 NSCLC patients. These images are typically reviewed by pathologists for cell abnormalities indicating cancer progression. The AI was tested with 40 additional biopsy images to assess its ability to predict brain metastases, demonstrating a striking 87% accuracy, surpassing the 57% accuracy rate of four expert pathologists.

Notably, the AI's predictions were even more accurate for the earliest-stage NSCLC patients (stage I) and were based on standard microscopic slides. The researchers believe that incorporating more data, such as disease severity and biomarkers, could enhance the AI's predictive capabilities. However, the researchers caution that this is just an initial step, and a larger study is necessary to validate these findings. Interestingly, the AI doesn't explicitly reveal the factors influencing its predictions, prompting ongoing research to decode the complex tumor cell features and their environment it might be analyzing. Going forward, Caltech scientists aim to develop improved instrumentation and procedures for collecting uniform, high-quality biopsy images, which could further refine the accuracy of AI predictions in cancer treatment.

"Overtreatment of cancer patients is a big problem," said Changhuei Yang, the Thomas G. Myers Professor of Electrical Engineering, Bioengineering, and Medical Engineering at Caltech. "Our pilot study indicates that AI may be very good at telling us in particular which patients are very unlikely to develop brain cancer metastasis."

"Our study is an indication that AI methods may be able to make meaningful predictions that are specific and sensitive enough to impact patient management," added Richard Cote, head of the Department of Pathology & Immunology at WUSTL.

Related Links:
Caltech
WUSTL

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.